PaoChi Chu - ACRO Biomedical President CEO, CFO, Secretary, Director
| ACBM Stock | USD 0 0.00 0.00% |
CEO
Mr. PaoChi Chu serves as President, Chief Executive Officer, Chief Financial Officer, Secretary, Director of the Company. Mr. Chu was our chief executive officer, chief financial officer, president, secretary and a director since January 30, 2017. Mr. Chu has served as the chairman of Mucho Biotech Co., Ltd., Mucho Furich Co., Ltd., and Mucho Biomedical Co., Ltd., companies engaged in applications of cordyceps since 2006 and which are controlled by Mr. Chu. Mr. Chu has more than ten years of experience in the biotech industry with a focus on initiating the integration of cordyceps technology development, which includes cordyceps strains management, cordyceps cultivation, food processing and health products development. Mr. Chu is a graduate of Fu Jen Catholic University in Taipei, Taiwan. since 2017.
| Age | 69 |
| Tenure | 7 years |
| Phone | 317 286 6788 |
| Web | https://acrobiomedicalco.com |
ACRO Biomedical Management Efficiency
The company has return on total asset (ROA) of (15.4974) % which means that it has lost $15.4974 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (29.7809) %, meaning that it created substantial loss on money invested by shareholders. ACRO Biomedical's management efficiency ratios could be used to measure how well ACRO Biomedical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 7 records | CEO Age | ||
| Jon Congleton | Mineralys Therapeutics, Common | 61 | |
| Junyuan Wang | Nuvation Bio | 51 | |
| Richard Cunningham | Anebulo Pharmaceuticals | 53 | |
| Mark Manfredi | Ikena Oncology | 53 | |
| David Hung | Nuvation Bio | 63 | |
| PharmD BCPS | Xilio Development | 49 | |
| Markus MD | Monte Rosa Therapeutics | 53 | |
Management Performance
| Return On Equity | -29.78 | |||
| Return On Asset | -15.5 |
ACRO Biomedical Leadership Team
Elected by the shareholders, the ACRO Biomedical's board of directors comprises two types of representatives: ACRO Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ACRO. The board's role is to monitor ACRO Biomedical's management team and ensure that shareholders' interests are well served. ACRO Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ACRO Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ChengHsiang Kao, Managing Director | ||
| PaoChi Chu, President CEO, CFO, Secretary, Director | ||
| YunYuan Chu, Managing Director | ||
| AnTao Fong, Managing Director | ||
| CheLi Lin, VP Technical |
ACRO Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ACRO Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -29.78 | |||
| Return On Asset | -15.5 | |||
| Operating Margin | (17.61) % | |||
| Current Valuation | 240.18 M | |||
| Shares Outstanding | 60.04 M | |||
| Shares Owned By Insiders | 49.97 % | |||
| Price To Book | 487.98 X | |||
| Price To Sales | 267.90 X | |||
| Revenue | 1.2 M | |||
| Gross Profit | 259.5 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in ACRO Pink Sheet
ACRO Biomedical financial ratios help investors to determine whether ACRO Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ACRO with respect to the benefits of owning ACRO Biomedical security.